latest news releases from the newsroom
Ahold CFO Hannu Ryopponen Accepts new Career Challenge
ZAANDAM, Netherlands, May 24, 2005 (PRIMEZONE) -- Ahold today announced that CFO Hannu Ryopponen has decided to accept a new position outside the company. He will remain Ahold CFO until August 31, 2005, and will become CFO and deputy to the CEO of Stora Enso as of September 1, 2005.
Galapagos Announces Changes to Board of Directors
MECHELEN, Belgium, May 24, 2005 (PRIMEZONE) -- Galapagos NV, a genomics-based drug discovery company, announces changes to its Board of Directors. In view of Galapagos' listing on Euronext Amsterdam and Euronext Brussels, Galapagos' Board has changed in composition. Ferdinand Verdonck has joined Galapagos as Independent Director, while Harrold van Barlingen has joined as Dependent Director.Mr. Verdonck (62) most recently was managing director of Almanij (then parent company of and now merged with KBC). He currently is on the board of several companies, including Banco Urquijo (Spain) and Dictaphone (USA). He has a professional background in financial services. His responsibilities entailed board participation in publicly traded and privately-held companies in many countries. He holds a law degree from the KU Leuven and degrees in economics from KU Leuven and the University of Chicago.
Actelion Ltd: Long-Term Tracleer (bosentan) Safety Profile Confirmed with Completion of Non-Interventional Program in Almost 5,000 Patients
SAN DIEGO, May 24, 2005 (PRIMEZONE) -- Actelion Ltd (Other OTC:ALIOF) (SWX:ATLN) announced that data from almost 5,000 Tracleer(R)-treated patients amounting to 3,416 patient-years of treatment were presented on Monday at the American Thoracic Society (ATS) meeting in San Diego. The long-term data collected between May 2002 and November 2004 confirm the safety profile of bosentan as seen in phase III clinical trials and provides information on the combination of treatments such as sildenafil or anticoagulants and bosentan. This data (the TRAcleer(R) eXcellence Post-Marketing Surveillance -- TRAX PMS -- Programme) represents the completion of the largest non-interventional study to date of patients treated with bosentan for PAH in daily medical practice.
Innova Holdings, Inc.
Innova Holdings, Inc. Receives SEC Subpoena Regarding 2003 Transactions
FORT MYERS BEACH, Fla., May 23, 2005 (PRIMEZONE) -- Innova Holdings, Inc. (the "Company") (OTCBB:IVHG) announced today that it received a subpoena from the U.S. Securities and Exchange Commission relating to an investigation concerning trading in certain OTC stocks. The subpoena seeks documents relating to merger and financing transactions engaged in by the Company in April 2003.